AMNI Stock Overview
Develops stem cell-based therapeutics to treat severe life-threatening diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Amniotics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.006 |
| 52 Week High | SEK 0.14 |
| 52 Week Low | SEK 0.0012 |
| Beta | 0.47 |
| 11 Month Change | 9.09% |
| 3 Month Change | 66.67% |
| 1 Year Change | -92.68% |
| 33 Year Change | -99.95% |
| 5 Year Change | n/a |
| Change since IPO | -99.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| AMNI | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 3.4% | -2.4% | -4.3% |
| 1Y | -92.7% | 18.0% | 12.6% |
Return vs Industry: AMNI underperformed the Swedish Biotechs industry which returned 18% over the past year.
Return vs Market: AMNI underperformed the Swedish Market which returned 12.6% over the past year.
Price Volatility
| AMNI volatility | |
|---|---|
| AMNI Average Weekly Movement | 30.4% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: AMNI's share price has been volatile over the past 3 months.
Volatility Over Time: AMNI's weekly volatility (30%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 6 | Marcus Larsson | www.amniotics.com |
Amniotics AB (publ) develops stem cell-based therapeutics to treat severe life-threatening diseases. The company’s lead drug candidate is PulmoStem for the treatment of lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; CutiStem for the treatment of dermatological indications; and AMNI-NK003.
Amniotics AB (publ) Fundamentals Summary
| AMNI fundamental statistics | |
|---|---|
| Market cap | SEK 16.40m |
| Earnings (TTM) | -SEK 30.87m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs AMNI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMNI income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 30.87m |
| Earnings | -SEK 30.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 20, 2024
| Earnings per share (EPS) | -0.011 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AMNI perform over the long term?
See historical performance and comparison